Literature DB >> 15917554

In vitro and in vivo activities of DA-7867, a new oxazolidinone, against aerobic gram-positive bacteria.

Eun Jeong Yoon1, Yeong Woo Jo, Sung Hak Choi, Tae Ho Lee, Jae Keol Rhee, Moohi Yoo, Mi Ja Shim, Eung Chil Choi.   

Abstract

In vitro and in vivo activities of DA-7867 were assessed against methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and penicillin-resistant Streptococcus pneumoniae. All isolates were inhibited by DA-7867 at <or=0.78 microg/ml, a four-times-lower concentration than that of inhibition by linezolid. For murine infection models, DA-7867 also exhibited greater efficacy than linezolid against all isolates tested.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15917554      PMCID： PMC1140508          DOI： 10.1128/AAC.49.6.2498-2500.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium.

Authors:  Inmaculada A Herrero; Nicolas C Issa; Robin Patel
Journal:  N Engl J Med       Date:  2002-03-14       Impact factor: 91.245

2.  Inhibition of group A streptococcus infection by carboxyfullerene.

Authors:  N Tsao; T Y Luh; C K Chou; J J Wu; Y S Lin; H Y Lei
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria.

Authors:  Dongeun Yong; Jong Hwa Yum; Kyungwon Lee; Yunsop Chong; Sung Hak Choi; Jae Keol Rhee
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

4.  Pharmacokinetics of DA-7867, a new oxazolidinone, after intravenous or oral administration to rats: intestinal first-pass effect.

Authors:  Soo K Bae; Won-Suk Chung; Eun J Kim; Jae K Rhee; Jong W Kwon; Won B Kim; Myung G Lee
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

5.  Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.

Authors:  R D Gonzales; P C Schreckenberger; M B Graham; S Kelkar; K DenBesten; J P Quinn
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

Review 6.  Linezolid Pharmacia Corp.

Authors:  J F Barrett
Journal:  Curr Opin Investig Drugs       Date:  2000-10

7.  Linezolid resistance in a clinical isolate of Staphylococcus aureus.

Authors:  S Tsiodras; H S Gold; G Sakoulas; G M Eliopoulos; C Wennersten; L Venkataraman; R C Moellering; M J Ferraro
Journal:  Lancet       Date:  2001-07-21       Impact factor: 79.321

Review 8.  Linezolid in vitro: mechanism and antibacterial spectrum.

Authors:  David M Livermore
Journal:  J Antimicrob Chemother       Date:  2003-05       Impact factor: 5.790

9.  Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds.

Authors:  J S Daly; G M Eliopoulos; E Reiszner; R C Moellering
Journal:  J Antimicrob Chemother       Date:  1988-06       Impact factor: 5.790

10.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Authors:  Hilmar Wisplinghoff; Tammy Bischoff; Sandra M Tallent; Harald Seifert; Richard P Wenzel; Michael B Edmond
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079
View more
  1 in total

1.  Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones.

Authors:  E E McKee; M Ferguson; A T Bentley; T A Marks
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.